• 18 May 2018

    BeiGene enrols first patient in Phase III trial of pamiparib

    BeiGene has enrolled the first patient in a Phase III clinical trial evaluating pamiparib (BGB-290), an investigational PARP inhibitor, as a potential maintenance therapy to treat patients with platinum-sensitive recurrent...

  • 17 May 2018

    Oncternal starts CIRLL study of cirmtuzumab and ibrutinib

    Oncternal Therapeutics has started the CIRLL study, a Phase Ib/II clinical trial of cirmtuzumab and ibrutinib combination for the treatment of patients with B-cell malignancies, including mantle cell lymphoma (MCL)...